Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692770 · ClinicalTrials.gov registry record · Phase 3
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
A Phase 3 study of Carcinoma, Hepatocellular, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,114
- Enrollment target
- 20
- Study locations
NCT00692770: Completed Phase 3 study of Carcinoma, Hepatocellular, sponsored by Bayer.
NCT00692770 is a Phase 3 study of Carcinoma, Hepatocellular that has completed, run by Bayer. The registered enrollment target is 1,114 participants, above the 571-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00692770, a Phase 3 study of Carcinoma, Hepatocellular, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,114 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
Primary Outcome
Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independen
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nexavar (Sorafenib, BAY43-9006)
Study Locations (20)
California
- - Los Angeles
- - Los Angeles
- - San Francisco
Massachusetts
- - Boston
- - Boston
- - Burlington
Minnesota
- - Minneapolis
- - Minneapolis
Alabama
- - Birmingham
Arizona
- - Phoenix
District of Columbia
- - Washington D.C.
Florida
- - Miami
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,114 participants |
| Start Date | 2008-08-15 |
| Est. Completion | 2014-11-28 |
| Phase | Phase 3 |
What the finished NCT00692770 record still lists
NCT00692770 is an interventional study that assigns participants to a tested intervention. Its 1,114 participants enrollment target places it among the larger protocols in the corpus, above the 571-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (95% higher).
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00692770 names 20 study sites across 15 states, led by California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00692770 about?
NCT00692770 is a clinical study titled "Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)". To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
What is the current status of trial NCT00692770?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,114 participants. The study started on 2008-08-15. Estimated completion is 2014-11-28.
What conditions does trial NCT00692770 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT00692770?
The interventions under investigation include: Placebo (DRUG), Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00692770?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00692770 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00692770's enrollment target sits among peer trials
1,114 3rd of 27 higher than 25 of 27 other Carcinoma, Hepatocellular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
COMPLETED · Phase 3
-
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
COMPLETED · Phase 3
-
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
COMPLETED · Phase 3
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI